Hinge Health officer proposes $4.39M share sale
The shares proposed for sale were acquired through restricted stock unit vesting; the notice also records two earlier sales under Rule 10b5-1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Hinge Health, Inc. officer James Budge reported a proposed sale of 35,907 common shares, with an aggregate market value of $4,387,476.33 and an approximate sale date of November 10, 2026. The shares were acquired upon vesting of restricted stock units during May 21, 2025 through November 1, 2026. The notice identifies June 11, 2026 as the adoption date for the Rule 10b5-1 plan.
It also lists two earlier 10b5-1 sales: 47,720 shares on October 12, 2026, for gross proceeds of $4,921,579.29, and 55,561 shares on September 10, 2026, for gross proceeds of $4,969,997.03.
Key Figures
Key Terms
restricted stock units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier HNGE sales did James Budge report?
AI-generated analysis. How Rhea-AI works. Not financial advice.